STAT+: Did the Trump administration just cut Novo a huge financial win?
The White House's GENEROUS plan was designed to make drugs more affordable for Medicaid users. There's one glaring potential exception.
STAT+ delves into whether the Trump administration may have just delivered a significant financial boon to Novo Nordisk. The outlet previously reported on the advantageous deals struck by both Eli Lilly and Novo Nordisk to lower the costs of obesity drugs for seniors under the Trump administration. According to the latest piece, Novo Nordisk may have received an additional advantage in these negotiations. Readers interested in the full story can continue their read on STAT+.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
